[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Peter Suzman @Biomaven on x 8504 followers
Created: 2025-07-18 14:59:44 UTC
The Eylea biosimilar space is a bit of a mess right now. $REGN formulation patent seems to expire in 2027, but they have a deal for another competitor to enter in 2026 and $AMGN is already on the market at-risk (they don't use a buffer). So likely for $HROW this will be a 2027 story, but same dynamics apply as for Lucentis. So then I would see tremendous financial incentives for payers to require Eylea biosimilar step-therapy before paying for Eylea HD or Vabysmo.
XXXXX engagements
Related Topics $hrow $regn regeneron pharmaceuticals inc stocks healthcare $amgn